SCLX on Nasdaq
Scilex Holding Co
In its 2026 annual report the company says: “We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.”4 It is headquartered in Palo Alto, California.1 Its shares trade on Nasdaq under the symbol SCLX.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Scholar Rock Holding Corp, Precision BioSciences or X4 Pharmaceuticals, Inc, or pick any stock.
- TickerSCLX on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersPalo Alto, California1
- Incorporated inDE2
- Business address960 San Antonio Road, Palo Alto, Ca 943032
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
415.8%Gross margin5
-1143.7%Operating margin5
-1236.4%Net margin5
-46.5%Revenue growth, 20255
$3.7MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue4¢$10.6M
- Research and development7¢$20.7M
- Selling, general and admin89¢$266.9M
- Income tax0¢$26.0K
Out of $30.3M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending3¢$133.0K
- Kept or used elsewhere97¢$3.7M
Out of $3.8M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Revenue | $30.3M | $56.6M |
| Cost of revenue | $10.6M | $16.7M |
| Research and development | $20.7M | $9.6M |
| Selling, general and administrative | $266.9M | $119.0M |
| Goodwill impairment | $73.4M | $0 |
| Intangible amortization | $4.4M | $4.0M |
| Legal settlements | $345.0K | -$9.4M |
| Total net operating costs and expenses | $376.3M | $140.0M |
| Loss from operations | -$346.0M | -$83.4M |
| (Gain) loss on derivative liability | $22.7M | -$17.4M |
| Change in fair value of debt and liability instruments | $25.4M | $4.8M |
| Interest expense, net | $11.5M | $2.0M |
| Loss on foreign currency exchange | -$86.0K | $45.0K |
| Unrealized loss on digital assets, net | $12.2M | $0 |
| Loss on debt extinguishment, net | $7.4M | $0 |
| Realized loss on digital assets, net | $30.2M | $0 |
| Unrealized (gain) on equity investment, net | -$2.7M | $0 |
| Realized (gain) on equity investments, net | -$19.2M | $0 |
| Unrealized (gain) on equity method investments carried at fair value, net | -$54.8M | $0 |
| Realized (gain) on equity method investments carried at fair value, net | -$4.7M | $0 |
| Realized (gain) on securities | $199.0K | $0 |
| Total other (income) expense, net | $28.0M | -$10.6M |
| Loss before income taxes | -$374.0M | -$72.8M |
| Income tax expense (benefit) | $26.0K | -$1.0K |
| Net loss | -$374.1M | -$72.8M |
| Net Loss Attributable to Common Stockholders Before Deemed Dividend | -$358.7M | -$72.8M |
| Deemed dividend | -$43.8M | $0 |
| Net loss attributable to noncontrolling interests | -$15.3M | $0 |
| Net Income (Loss) Available to Common Stockholders, Basic, Total | -$402.5M | -$72.8M |
| Net comprehensive loss attributable to common stockholders | -$358.7M | -$72.8M |
| Net loss per share attributable to common stockholders - basic | -$36.48 | -$7.24 |
| Net loss per share attributable to common stockholders - diluted | -$36.48 | -$8.05 |
| Weighted average number of shares during the period-basic | 11.0K shares | 10.1K shares |
| Weighted average number of shares, diluted | 11.0K shares | 10.1K shares |
| Foreign currency translation adjustment | -$756.0K | $0 |
| Changes in fair value attributable to instrument-specific credit risk | -$11.4M | $6.3M |
| Total other comprehensive income | -$12.1M | $6.3M |
| Comprehensive loss attributable to common stockholders | -$370.9M | -$66.5M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $5.0M | $3.3M | |||
| Marketable securities | $6.0M | $0 | |||
| Accounts receivable, net | $15.2M | $26.4M | |||
| Inventory | $4.8M | $2.4M | |||
| Prepaid expenses and other current assets | $7.3M | $9.4M | |||
| Total current assets | $38.4M | $41.5M | |||
| Property and equipment, net | $13.6M | $708.0K | |||
| Operating lease right-of-use asset | $14.8M | $2.2M | |||
| Intangibles, net | $59.1M | $32.5M | |||
| Investments | $1.0M | $2.4M | |||
| Equity method investment, at fair value | $127.0M | $0 | |||
| Digital assets | $64.7M | $0 | |||
| Goodwill | $13.5M | $13.5M | |||
| Other long-term assets | $523.0K | $119.0K | |||
| Total assets | $365.0M | $93.0M | |||
| Accounts payable | $86.3M | $52.6M | |||
| Accrued payroll | $3.3M | $1.5M | |||
| Accrued rebates and fees | $231.8M | $162.5M | |||
| Accrued expenses | $66.4M | $2.8M | |||
| Current portion of deferred consideration | $407.0K | $447.0K | |||
| Debt, current | $83.3M | $34.9M | |||
| Promissory notes | $3.5M | $0 | |||
| Purchased revenue liability, current | $3.8M | $4.1M | |||
| Current portion of operating lease liabilities | $1.7M | $714.0K | |||
| Other current liabilities | $3.3M | $0 | |||
| Total current liabilities | $483.7M | $259.6M | |||
| Long-term portion of deferred consideration | $2.0M | $2.4M | |||
| Debt, net of issuance costs | $22.5M | $845.0K | |||
| Purchased revenue liability, net of current portion | $4.6M | $2.7M | |||
| Derivative liabilities | $50.6M | $18.3M | |||
| Operating lease liabilities, net of current portion | $13.2M | $1.5M | |||
| Other long-term liabilities | $174.0K | $155.0K | |||
| Total liabilities | $576.7M | $285.6M | |||
| Common stock, $0.0001 par value, 740,000,000 shares authorized; 8,491,267 shares issued and 7,033,004 shares outstanding as of December 31, 2025; 6,951,622 shares issued and 5,235,377 shares outstanding as of December 31, 2024 | $1.0K | $1.0K | |||
| Additional paid-in capital | $796.7M | $454.6M | |||
| Accumulated other comprehensive income | -$5.8M | $6.3M | |||
| Accumulated deficit | -$921.8M | -$563.1M | |||
| Treasury stock, at cost; 1,458,263 shares as of December 31, 2025 and 1,716,245 as of December 31, 2024 | -$76.9M | -$90.5M | |||
| Total stockholders' deficit before noncontrolling interests | -$207.8M | -$192.6M | |||
| Noncontrolling interests | -$4.0M | $0 | |||
| Total stockholders' deficit | -$211.8M | -$192.6M | -$172.9M | ||
| Total liabilities and stockholders' deficit | $365.0M | $93.0M | |||
| Preferred Stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 740.0M shares | 740.0M shares | |||
| Common stock, shares issued | 8.5M shares | 7.0M shares | 3.2M shares | 3.2M shares | |
| Common stock, shares outstanding | 7.0M shares | 5.2M shares | |||
| Treasury stock shares | 1.5M shares | 1.7M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $5.0M | $3.3M | |||
| Marketable securities | $6.0M | $0 | |||
| Accounts receivable, net | $15.2M | $26.4M | |||
| Inventory | $4.8M | $2.4M | |||
| Prepaid expenses and other current assets | $7.3M | $9.4M | |||
| Total current assets | $38.4M | $41.5M | |||
| Property and equipment, net | $13.6M | $708.0K | |||
| Operating lease right-of-use asset | $14.8M | $2.2M | |||
| Intangibles, net | $59.1M | $32.5M | |||
| Investments | $1.0M | $2.4M | |||
| Equity method investment, at fair value | $127.0M | $0 | |||
| Digital assets | $64.7M | $0 | |||
| Goodwill | $13.5M | $13.5M | |||
| Other long-term assets | $523.0K | $119.0K | |||
| Total assets | $365.0M | $93.0M | |||
| Accounts payable | $86.3M | $52.6M | |||
| Accrued payroll | $3.3M | $1.5M | |||
| Accrued rebates and fees | $231.8M | $162.5M | |||
| Accrued expenses | $66.4M | $2.8M | |||
| Current portion of deferred consideration | $407.0K | $447.0K | |||
| Debt, current | $83.3M | $34.9M | |||
| Promissory notes | $3.5M | $0 | |||
| Purchased revenue liability, current | $3.8M | $4.1M | |||
| Current portion of operating lease liabilities | $1.7M | $714.0K | |||
| Other current liabilities | $3.3M | $0 | |||
| Total current liabilities | $483.7M | $259.6M | |||
| Long-term portion of deferred consideration | $2.0M | $2.4M | |||
| Debt, net of issuance costs | $22.5M | $845.0K | |||
| Purchased revenue liability, net of current portion | $4.6M | $2.7M | |||
| Derivative liabilities | $50.6M | $18.3M | |||
| Operating lease liabilities, net of current portion | $13.2M | $1.5M | |||
| Other long-term liabilities | $174.0K | $155.0K | |||
| Total liabilities | $576.7M | $285.6M | |||
| Common stock, $0.0001 par value, 740,000,000 shares authorized; 8,491,267 shares issued and 7,033,004 shares outstanding as of December 31, 2025; 6,951,622 shares issued and 5,235,377 shares outstanding as of December 31, 2024 | $1.0K | $1.0K | |||
| Additional paid-in capital | $796.7M | $454.6M | |||
| Accumulated other comprehensive income | -$5.8M | $6.3M | |||
| Accumulated deficit | -$921.8M | -$563.1M | |||
| Treasury stock, at cost; 1,458,263 shares as of December 31, 2025 and 1,716,245 as of December 31, 2024 | -$76.9M | -$90.5M | |||
| Total stockholders' deficit before noncontrolling interests | -$207.8M | -$192.6M | |||
| Noncontrolling interests | -$4.0M | $0 | |||
| Total stockholders' deficit | -$211.8M | -$192.6M | -$172.9M | ||
| Total liabilities and stockholders' deficit | $365.0M | $93.0M | |||
| Preferred Stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 45.0M shares | 45.0M shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 740.0M shares | 740.0M shares | |||
| Common stock, shares issued | 8.5M shares | 7.0M shares | 3.2M shares | 3.2M shares | |
| Common stock, shares outstanding | 7.0M shares | 5.2M shares | |||
| Treasury stock shares | 1.5M shares | 1.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$374.1M | -$72.8M |
| Depreciation and amortization | $4.6M | $4.0M |
| Amortization of debt issuance costs and debt discount | $409.0K | $316.0K |
| Non-cash operating lease cost | $812.0K | $718.0K |
| Stock-based compensation | $15.5M | $15.7M |
| Fair value of Gloperba-Elyxyb RPA liability expensed | $500.0K | $0 |
| Fair value of treasury Stock expensed - Tranche B and Oramed Note | $3.6M | $0 |
| Fair value of September 2025 warrants expensed - Tranche B modification | $3.1M | $0 |
| (Gain) loss on derivative liability | $22.7M | -$17.4M |
| Loss on debt extinguishment, net | $7.3M | $0 |
| Goodwill impairment | $73.4M | $0 |
| Financing costs and allocated expense for financial instruments at fair value | $0 | $17.3M |
| In-process research and development expense | $5.4M | $0 |
| Transaction costs expensed related to Semnur Business Combination | $140.0M | $0 |
| Change in fair value of debt and liability instruments | $25.4M | $4.8M |
| Change in fair value of equity investments | -$2.7M | $0 |
| Change in fair value of digital assets | $12.2M | $0 |
| Change in fair value of equity method investment, net | -$54.8M | $0 |
| Realized (gain) loss on investment, net | -$19.2M | $0 |
| Realized (gain) loss on digital assets, net | $30.2M | $0 |
| Realized (gain) loss on equity method investment, net | -$4.7M | $0 |
| Realized Gains & Losses on Securities | $199.0K | $0 |
| Allowances for expected credit losses | $0 | $1.2M |
| Other | -$13.0K | $661.0K |
| Accounts receivables, net | $13.8M | -$6.3M |
| Inventory | $1.8M | $1.5M |
| Prepaid expenses and other | $3.3M | -$479.0K |
| Other long-term assets | -$3.0K | -$30.0K |
| Accounts payable | $13.1M | $7.4M |
| Accrued Payroll | -$1.1M | -$1.2M |
| Accrued expenses | $14.6M | -$8.2M |
| Accrued rebates and fees | $69.2M | $72.9M |
| Operating lease liability | -$857.0K | -$758.0K |
| Other long-term liabilities | $25.0K | -$24.0K |
| Net cash (used for) proceeds from operating activities | $3.8M | $19.3M |
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | -$600.0K | -$600.0K |
| Purchase of equity securities | $0 | -$2.0M |
| Cash paid for in-process research and development, net | -$200.0K | -$75.0K |
| Cash paid to settle Datavault Obligation | -$9.2M | $0 |
| Purchases of Bitcoin with cash | -$15.8M | $0 |
| Purchase of property, plant, and equipment | -$133.0K | $0 |
| Exercise of prefunded warrant | -$27.0K | $0 |
| Purchase of preferred shares of Vivasor | -$9.0M | $0 |
| Sale of Datavault AI Inc. shares for cash, net | $39.6M | $0 |
| Repayments on promissory note | -$962.0K | $0 |
| Payment made for PA OPS investment | -$1.0M | $0 |
| Vivasor Cash Acquired | $1.5M | $0 |
| Purchase of convertible promissory note from Denali | -$50.0K | $0 |
| Net cash used for investing activities | $4.1M | -$2.7M |
| Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement | $0 | $2.7M |
| Proceeds from issuance of Revolving Facility | $0 | $95.4M |
| Proceeds from issuance of FSF Deposit | $0 | $10.0M |
| Proceeds from issuance of Tranche B Notes and purchased revenue liability | $0 | $25.0M |
| Repayment of Revolving Facility | $0 | -$112.8M |
| Repayment of Oramed Note | $0 | -$64.2M |
| Cash consideration paid in connection with warrant repurchase | $0 | -$300.0K |
| Cash assumed in Semnur Business Combination | $35.0K | $0 |
| Repayment of Convertible Debentures | $0 | -$4.4M |
| Repayment of Tranche B Notes | -$20.5M | -$3.3M |
| Payments of debt issuance costs | -$71.0K | -$4.2M |
| Cash consideration paid in connection with the repurchase of Penny Warrants | -$27.0M | $0 |
| Payments on purchased revenue liability | -$3.2M | $0 |
| Transaction costs paid in connection with share repurchase | -$996.0K | $0 |
| Proceeds from exercise of April 2024 RDO Warrants and December 2024 RDO Warrants | $20.4M | $0 |
| Transaction costs paid in connection with issuance of common stock and exchange of April 2024 RDO Warrants and December 2024 RDO Warrants for November 2025 Warrants | -$1.7M | $0 |
| Payments for the termination of Tumim Purchase Agreement | -$2.7M | $0 |
| Proceeds from issuance of Scilex-St. James Loans | $21.5M | $0 |
| Excise tax paid in connection with share repurchase | -$860.0K | -$450.0K |
| Proceeds from issuance of shares under direct offerings | $0 | $42.0M |
| Payments of direct offering issuance costs | $0 | -$4.4M |
| Payments of deferred transaction costs related to Semnur Merger | $0 | -$1.4M |
| Proceeds from exercise of December 2024 RDO Warrants for Common Stock | $10.2M | $0 |
| Proceeds from stock options and warrants exercised and ESPP | $23.0K | $2.1M |
| Payments for Vivasor debt | -$558.0K | $0 |
| Payments in lieu of fractional shares for Reverse Stock Split | -$1.0K | $0 |
| Net cash (used for) financing activities | -$5.5M | -$18.1M |
| Effect of exchange rate changes on cash | -$756.0K | $0 |
| Net change in cash and cash equivalents | $1.7M | -$1.5M |
| Cash paid for interest | $935.0K | $1.6M |
| Issuance costs related to direct offerings included in accrued expenses and account payables | $0 | $1.8M |
| Net liabilities assumed in Semnur Business Combination | $12.8M | $0 |
| Derecognition of Scilex's equity investment in Denali in connection with Semnur Business Combination | $2.5M | $0 |
| Exercise of December 2024 RDO Warrants in exchange for settlement of Tranche B Notes principal and interest | $2.7M | $0 |
| Purchase of equity investment in Datavault AI Inc in exchange for Bitcoin | $8.1M | $0 |
| Bitcoin acquired in exchange for shares of Semnur Stock | $200.0M | $0 |
| Additions to intangible assets included in accrued expenses | $1.0M | $0 |
| Fee Warrants issued and exercised in connection with the Commitment Letter | $0 | $610.0K |
| Settlement of FSF Deposit | $0 | $13.0M |
| Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable | $0 | $4.6M |
| Conversion of Oramed Note into Tranche B Notes | $0 | $25.0M |
| Conversion of Tranche B Notes into common stock | $0 | $9.3M |
| Debt issuance costs included in accrued expenses | $0 | $3.1M |
| Placement Agent Shares and October 2024 Placement Agent Warrants | $0 | $3.8M |
| StockBlock Warrants issued in connection with the December 2024 RDO | $0 | $1.3M |
| Datavault Licenses acquired but not yet paid | $30.0M | $0 |
| Purchase of Bitcoin in exchange for Scilex-St. James Loans | $9.4M | $0 |
| Excise tax in connection with share repurchase included in accrued expenses | $0 | $860.0K |
| Purchase and exercise of prefunded warrant for Datavault shares in exchange for Bitcoin | $110.0M | $0 |
| Issuance of warrants as financing costs in connection with issuance of common stock and exchange of liability classified instruments | $862.0K | $0 |
| Vivasor debt forgiveness | -$2.5M | $0 |
| Vivasor net assets consolidated | $0 | $0 |
| Net impact of the issuance of November 2025 Warrants and exchange of liability classified instruments | $6.2M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Scilex Holding Co sits at the top of its group. 12 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Scilex Holding Co
- SCLX Stock Acquisition JV LLC Filed SCHEDULE 13D/A on Scilex Holding Co, latest Jul 7, 2026 (7 filings since Sep 29, 2023)
- Oramed Pharmaceuticals Filed SCHEDULE 13G/A on Scilex Holding Co, latest Feb 13, 2026 (5 filings since Jan 17, 2025)
- Semnur, Inc. Filed SCHEDULE 13D on Scilex Holding Co, latest Sep 26, 2025
- Sorrento Therapeutics Filed SC 13D/A on Scilex Holding Co, latest Sep 26, 2023 (5 filings since Nov 17, 2022)
- Hudson Bay Capital Management LP Filed SC 13G/A on Scilex Holding Co, latest Feb 13, 2023 (2 filings since Feb 3, 2022)
- Karpus Management, Inc. Filed SC 13G/A on Scilex Holding Co, latest Dec 9, 2022 (2 filings since Jan 10, 2022)
- Lawrence Feis Filed SC 13G/A on Scilex Holding Co, latest Nov 14, 2022 (2 filings since Jul 27, 2022)
- CVI Investments, Inc. Filed SC 13G/A on Scilex Holding Co, latest Feb 14, 2022
- Shaolin Capital Management LLC Filed SC 13G on Scilex Holding Co, latest Feb 11, 2022
- Space Summit Capital LLC Filed SC 13G/A on Scilex Holding Co, latest Feb 2, 2022
- Scilex Holding Co Palo Alto, California
- Datavault AI Inc. Stake · Beaverton, Oregon
- Semnur Pharmaceuticals, Inc. Stake · Palo Alto, California
- Scilex (BVI), Limited Subsidiary · British Virgin Islands
- Scilex Bio, Inc. Subsidiary · Delaware, United States
- Scilex Pharmaceuticals Inc. Subsidiary · Delaware, United States
- Scilex, Inc. Subsidiary · Delaware, United States
- SCLX DRE Holdings LLC Subsidiary · Delaware, United States
- SCLX Stock Acquisition JV LLC Subsidiary · Texas, United States
- Semnur (BVI), Limited Subsidiary · British Virgin Islands
- Semnur Pharmaceuticals, Inc. Subsidiary · Delaware, United States
- Semnur, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.
What it owns
What Scilex Holding Co reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $13.9M5 Dec 31, 2025 | $772.0K5 Dec 31, 2024 | +1703.1% |
| Accumulated depreciation | $321.0K5 Dec 31, 2025 | $64.0K5 Dec 31, 2024 | +401.6% |
| Property and equipment, net | $13.6M5 Dec 31, 2025 | $708.0K5 Dec 31, 2024 | +1820.8% |
| Operating-lease assets (leased space) | $14.8M5 Dec 31, 2025 | $2.2M5 Dec 31, 2024 | +566.0% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $13.5M5 Dec 31, 2025 | $13.5M5 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $59.1M5 Dec 31, 2025 | $32.5M5 Dec 31, 2024 | +82.1% |
| Finite-lived intangibles, gross | $91.8M5 Dec 31, 2025 | $60.8M5 Dec 31, 2024 | +51.0% |
| Accumulated amortization | -$32.7M5 Dec 31, 2025 | -$28.3M5 Dec 31, 2024 | −15.4% |
| Finite-lived intangibles, net | $59.1M5 Dec 31, 2025 | $32.5M5 Dec 31, 2024 | +82.1% |
Inventory
Properties, in its own words
Our principal executive office is currently located in Palo Alto, California, and consists of approximately 12,500 square feet of leased office space. The lease term expires in September 2027. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms.
Item 2 of the 10-K filed Apr 10, 2026.4
Leadership
Who has led Scilex Holding Co, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerHenry Ji Oct 9, 2025 to now12
- ChairHenry Ji Nov 15, 2022 to now13
- PresidentHenry Ji Oct 9, 2025 to now12
Board members and other officers (17)
- OfficerElizabeth Czerepak Nov 15, 2022 to Jan 17, 202314
- OfficerChris Ho Jan 6, 2021 to Jan 6, 202115
- OfficerJeffrey Chi Jan 6, 2021 to Jan 6, 202115
- Board memberHenry Ji Oct 9, 2025 to now12
- Board memberAnnu Navani Aug 12, 2024 to Aug 19, 202416
- Board memberJay Chun Sep 25, 2023 to now17
- Board memberYue Alexander Wu Sep 25, 2023 to now18
- Board memberDavid Lemus Nov 15, 2022 to Oct 18, 202419
- Board memberDorman Followwill Nov 15, 2022 to now20
- Board memberLaura Hamill Nov 15, 2022 to Jan 17, 202321
- Board memberTien-Li Lee Nov 15, 2022 to Jan 17, 202322
- Board memberTommy Thompson Nov 15, 2022 to Jan 17, 202323
- Board memberChris Ho Jan 6, 2021 to Jan 6, 202115
- Board memberJeffrey Chi Jan 6, 2021 to Jan 6, 202115
- Board memberPei Wei Woo Jan 6, 2021 to Jan 6, 202124
- Board memberSteve Myint Jan 6, 2021 to Jan 6, 202125
- Board memberSuneel G. Kaji Jan 6, 2021 to Jan 6, 202126
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- SCLX DRE Holdings LLC Delaware3
- SCLX Stock Acquisition JV LLC Texas3
- Scilex (BVI), Limited British Virgin Islands3
- Scilex Bio, Inc. Delaware3
- Scilex Pharmaceuticals Inc. Delaware3
- Scilex, Inc. Delaware3
- Semnur (BVI), Limited British Virgin Islands3
- Semnur Pharmaceuticals, Inc. Delaware3
- Semnur, Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Sep 29, 20268-K Entered a material agreement29
- Aug 12, 20268-K Entered a material agreement30
- Jul 22, 20268-K Entered a material agreement; Completed an acquisition or sale31
- Jul 6, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure32
- Jun 29, 20268-K Entered a material agreement; Unregistered sale of shares33
- Jun 24, 20268-K Shareholder vote34
- May 11, 20268-K Other events35
- May 5, 20268-K Entered a material agreement; Regulation FD disclosure36
- Apr 28, 20268-K Entered a material agreement37
- Mar 13, 20268-K Regulation FD disclosure38
- Mar 13, 20268-K Regulation FD disclosure39
- Feb 20, 20268-K Entered a material agreement; Unregistered sale of shares40
- Oct 9, 2025New chief executive Henry Ji becomes CEO12
Calendar
Coming up
- Nov 13, 2026Reports results for the quarter ending Sep/202641
When it reported results
- Oct 8, 2024Reported quarterly or annual results42
- Aug 1, 2024Reported quarterly or annual results43
- Jul 1, 2024Reported quarterly or annual results44
- Apr 16, 2024Reported quarterly or annual results45
- Mar 5, 2024Reported quarterly or annual results46
- Jan 2, 2024Reported quarterly or annual results47
- Dec 1, 2023Reported quarterly or annual results48
- Nov 1, 2023Reported quarterly or annual results49
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
697 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 144 major events, 80 insider forms, 27 large holders, 2 private raises, 422 other. The latest 20:
- Sep 29, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Jul 22, 20268-K EDGAR
- Jul 7, 2026SCHEDULE 13D/A EDGAR
- Jul 7, 20264 EDGAR
- Jul 6, 20268-K EDGAR
- Jun 30, 2026S-8 EDGAR
- Jun 29, 20268-K EDGAR
- Jun 24, 20268-K EDGAR
- Jun 11, 2026EFFECT EDGAR
- Jun 9, 2026CORRESP EDGAR
- Jun 9, 2026UPLOAD EDGAR
- Jun 2, 2026S-3 EDGAR
- May 22, 2026EFFECT EDGAR
- May 20, 2026CORRESP EDGAR
- May 20, 202610-Q EDGAR
- May 15, 2026NT 10-Q EDGAR
- May 11, 20268-K EDGAR
- May 5, 2026DEFA14A EDGAR
The 697 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
19 open-market trades by officers, directors and large owners since October 2021: 15 buys and 4 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | Scilex Holding Co10% owner | Sale | 9,657,300 | $0.54 | $5.2M | Form 4 |
| Dec 29, 2025 | Scilex Holding Co10% owner | Sale | 7,310,984 | $0.66 | $4.8M | Form 4 |
| Dec 26, 2025 | Scilex Holding Co10% owner | Sale | 3,689,016 | $0.75 | $2.8M | Form 4 |
| Dec 18, 2024 | SHAH JAISIMSee Remarks | Buy | 30,000 | $0.46 | $13.8K | Form 4 |
| Oct 31, 2024 | Ji HenryExec Chair, CEO and President | Buy | 8,888 | $0.94 | $8.4K | Form 4 |
| Oct 29, 2024 | SHAH JAISIMSee Remarks | Buy | 32,000 | $0.99 | $31.7K | Form 4 |
| Oct 18, 2024 | Followwill DormanDirector | Buy | 1,000 | $0.99 | $990 | Form 4 |
| Oct 18, 2024 | Chun JayDirector | Buy | 5,000 | $0.95 | $4.8K | Form 4 |
| Oct 17, 2024 | Wu Yue AlexanderDirector | Buy | 20,000 | $0.95 | $19.0K | Form 4 |
| Oct 17, 2024 | Lemus DavidDirector | Buy | 2,000 | $0.90 | $1.8K | Form 4 |
| Oct 17, 2024 | Ji HenryExec Chair, CEO and President | Buy | 10,000 | $0.97 | $9.7K | Form 4 |
| Oct 16, 2024 | SHAH JAISIMSee Remarks | Buy | 30,000 | $0.99 | $29.7K | Form 4 |
| Oct 16, 2024 | Ma Stephen HoiCFO, COO and Secretary | Buy | 6,700 | $0.97 | $6.5K | Form 4 |
| May 17, 2024 | Ji HenryExec Chair, CEO and President | Buy | 50,000 | $0.88 | $44.0K | Form 4 |
| May 17, 2024 | Chun JayDirector | Buy | 57,500 | $0.90 | $51.8K | Form 4 |
| May 17, 2024 | SHAH JAISIMSee Remarks | Buy | 56,939 | $0.92 | $52.4K | Form 4 |
| May 17, 2024 | Ma Stephen HoiCFO, COO and Secretary | Buy | 14,140 | $0.88 | $12.4K | Form 4 |
| May 16, 2024 | SHAH JAISIMSee Remarks | Buy | 83,061 | $0.84 | $69.8K | Form 4 |
| Sep 21, 2023 | Sorrento Therapeutics, Inc.10% owner | Sale | 60,068,585 | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- SCLX Stock Acquisition JV LLCSCHEDULE 13D/A, 7 filings Sep 29, 2023 to Jul 7, 202650
- Oramed PharmaceuticalsSCHEDULE 13G/A, 5 filings Jan 17, 2025 to Feb 13, 202651
- Semnur, Inc.SCHEDULE 13D, 1 filing Sep 26, 202552
- Sorrento TherapeuticsSC 13D/A, 5 filings Nov 17, 2022 to Sep 26, 202353
- Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 3, 2022 to Feb 13, 202354
- Karpus Management, Inc.SC 13G/A, 2 filings Jan 10, 2022 to Dec 9, 202255
- Lawrence FeisSC 13G/A, 2 filings Jul 27, 2022 to Nov 14, 202256
- CVI Investments, Inc.SC 13G/A, 1 filing Feb 14, 202257
- Shaolin Capital Management LLCSC 13G, 1 filing Feb 11, 202258
- Space Summit Capital LLCSC 13G/A, 1 filing Feb 2, 202259
Stakes it holds
Scilex Holding Co has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).
- Datavault AI Inc.SCHEDULE 13D/A Oct 2, 2025 to Aug 24, 202660
- Semnur Pharmaceuticals, Inc.SCHEDULE 13D/A Sep 9, 2024 to Jun 26, 202661
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Henry JiPh.D. | $1.6M | $3.1M62 | |
| 2025 | Stephen Ma | 53 | $696.5K | $1.5M62 |
| 2025 | Jaisim Shah | $1.2M | $1.3M62 | |
| 2024 | Former Chief Executive OfficerPresident and Director | $1.2M | $1.3M62 | |
| 2024 | Chief Executive OfficerPresident and Executive Chairperson | $1.2M | $1.3M62 | |
| 2024 | Chief Financial OfficerChief Operating Officer, Senior Vice President and Secretary | $600.0K | $613.8K62 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $104.6M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2025 | $2.7M | $2.7M |
| 2023 | $101.9M | $101.9M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 70. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Scilex Holding Co is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARScilex Holding Co1
- CIK0001820190
- Employer ID (EIN)92-10625424
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address960 San Antonio Road, Palo Alto, CA 943031
- Phone(650) 516-43101
- Shares outstanding8,493,000 as of Aug 10, 202610
- Public float$32.4M as of Jun 30, 20254
- AuditorBPM LLP, Walnut Creek, California PCAOB ID 207; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceAug 19, 20201
- Filings742 in all: 424B3 (248), 8-K (144), 4 (70), CORRESP (27), 425 (26), EFFECT (23), 3 (21), UPLOAD (19)1
All 48 form types
10-Q (17), POS AM (11), S-1/A (10), S-1 (9), SCHEDULE 13D/A (9), S-4/A (8), DEF 14A (7), S-8 (7), SC 13D/A (7), 10-K (6), 424B5 (6), SC 13G (6), SC 13G/A (5), ARS (4), DEFA14A (4), NT 10-Q (4), S-3 (4), SCHEDULE 13G/A (4), 8-K/A (3), PRE 14A (3), SC 13D (3), SCHEDULE 13D (3), SEC STAFF LETTER (3), 10-Q/A (2), D (2), DRS (2), RW (2), 10-K/A (1), 25-NSE (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), NT 10-K (1), PRER14A (1), S-1MEF (1), S-3/A (1), S-4 (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Apr 10, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 30, 2026
Latest 8-K (8-K) Sep 29, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 per share | SCLX | Nasdaq |
From the cover page of the 10-K filed Apr 10, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks Scilex Holding Co names in Item 1A of its 10-K filed Apr 10, 2026: 74 risks under these headings, as written.4
- Risks Related to our Limited Operating History, Financial Condition and Capital Requirements
- Risks Related to our Commercial Operations and Product Development
- Risks Related to our Business and Operations
- Risks Related to our Intellectual Property
- Risks Related to Government Regulations
- Risks Related to Ownership of our Common Stock
- Risks Related to Cryptocurrency
- We currently have three commercial products, ZTlido, ELYXYB and GLOPERBA; but we are currently heavily dependent on the commercial success of ZTlido, as ELYXYB and GLOPERBA are in the initial stages of commercialization, and we may be unable to generate sufficient revenue to support our operations.
- We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future.
- The terms of the Oramed Note and the Tranche B Notes impose certain operating and financial covenants that restrict our operating and financial flexibility. and any failure to comply with such covenants could result in an event of default that could adversely affect our business, financial condition and results of operations.
- The Oramed Note and Tranche B Notes impose certain operating and financial covenants and any failure to comply with such covenants could result in an event of default that could adversely affect our business, financial condition and results of operations.
- We may not have the ability to raise the funds necessary to settle the Oramed Note or the Tranche B Notes in cash upon a change of control or other event of default, and any future debt may contain limitations on our ability to pay cash upon conversion of the Tranche B Notes.
The other 68 risks
- We may be unable to comply with the covenants of our debt agreements with The St. James Bank.
- We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved.
- We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.
- We may not be able to generate sufficient cash to service our indebtedness and other liquidity needs.
- Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern.
- We have previously identified material weaknesses in our internal control over financial reporting. If we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to timely and accurately report our financial results, and such material weaknesses may result in a material misstatement of our consolidated financial statements.
- We obtain, or historically have obtained, our commercial supply of certain of our products, the clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all.
- We rely on a single third-party logistics distribution provider for ZTlido, ELYXYB and GLOPERBA.
- If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business.
- We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.
- We may in the future enter into collaborations, in-licensing arrangements, joint ventures, or strategic alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenues.
- Delays in clinical trials could result in increased costs for us and delay our ability to obtain commercial approval and generate additional revenue.
- Our business could be adversely affected by the effects of health pandemics or other health crises, which could cause significant disruptions in our operations and those of our CMOs, CROs and other third parties upon whom we rely.
- Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates, and the approval may be for a more narrow indication than we seek.
- We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.
- The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
- We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us.
- The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA, ELYXYB or our product candidates, if approved, could decrease our ability to generate product revenue.
- Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.
- Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
- Interim “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.
- Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.
- Our business may suffer reputational harm due to failures of our product candidates.
- ZTlido, GLOPERBA and ELYXYB may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval.
- ZTlido, GLOPERBA, ELYXYB and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business.
- If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations.
- We may need to increase the size of our company and may not effectively manage our growth.
- There is no assurance that the Semnur Business Combination will actually maximize the value of Legacy Semnur and/or the SP-102 asset for us or our stockholders.
- Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
- Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations.
- We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive.
- International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States.
- The increasing use of social media platforms presents new risks and challenges.
- Our business and operations would suffer in the event of a system failure.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.
- We are substantially dependent on the intellectual property we in-license from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize SP-103 would be harmed.
- We are party to the Romeg License Agreement for the in-licensing of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg License Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed.
- There can be no assurance that we will successfully develop or commercialize the technology in-licensed pursuant to the Datavault License Agreement or the Vivasor-Datavault License Agreement.
- Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms.
- If we are unable to maintain patent protection for ZTlido, GLOPERBA, ELYXYB and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
- We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and in-licenses.
- We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.
- If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected.
- Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.
- We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.
- Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties.
- Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.
- If we do not obtain patent term extension and data exclusivity for any of our product candidates we are developing or may develop, our business may be materially harmed.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
- We may not be able to protect our intellectual property rights throughout the world.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed.
- Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage.
- The regulatory approval processes of the FDA and comparable non-U.S. regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. Moreover, gaining approval for a product candidate in one country or jurisdiction does not guarantee that we will be able to obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential.
- If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.
- Any approved product candidate will be subject to ongoing and continued regulatory requirements, which may result in significant expense and limit our ability to commercialize such products.
- A fast-track product designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.
- Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations.
- Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.
- Our business may be impacted by actions of the current U.S. administration, including executive orders, policies, new legislation and judicial decisions.
- Our business involves the use of hazardous materials and we and third parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Legal proceedings
The information required by this Item is incorporated by reference to Note 13 titled “Commitments and Contingencies” and Note 16 titled “Subsequent Events” of the Notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARHenry Ji, Chief executive officer
- 13SEC EDGARHenry Ji, Chair
- 14SEC EDGARElizabeth Czerepak, Officer
- 15SEC EDGARChris Ho, Officer
- 16SEC EDGARAnnu Navani, Board member
- 17SEC EDGARJay Chun, Board member
- 18SEC EDGARYue Alexander Wu, Board member
- 19SEC EDGARDavid Lemus, Board member
- 20SEC EDGARDorman Followwill, Board member
- 21SEC EDGARLaura Hamill, Board member
- 22SEC EDGARTien-Li Lee, Board member
- 23SEC EDGARTommy Thompson, Board member
- 24SEC EDGARPei Wei Woo, Board member
- 25SEC EDGARSteve Myint, Board member
- 26SEC EDGARSuneel G. Kaji, Board member
- 27
- 28
- 29SEC EDGAREntered a material agreement
- 30SEC EDGAREntered a material agreement
- 31
- 32
- 33
- 34SEC EDGARShareholder vote
- 35SEC EDGAROther events
- 36
- 37SEC EDGAREntered a material agreement
- 38SEC EDGARRegulation FD disclosure
- 39SEC EDGARRegulation FD disclosure
- 40
- 41NasdaqNasdaq calendar
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62